Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480145 | 0.85 | KMT2A (0.38) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL1480114 | 0.85 | KMT2A (0.38) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL1480929 | 0.85 | KMT2A (0.38) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL8214544 | 0.85 | KMT2A (0.42) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL940143 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL2529726 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL1480821 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL1481301 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL2531445 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 | |
| SCHEMBL940142 | 0.85 | KMT2A (0.40) | KMT2APARP1FABP5FABP7GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | KMT2A 1984/4885PARP1 3792/4885FABP5 3317/4885 |
| US-20110077254-A1 | COMPOUNDS | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | KMT2A 2801/4885PARP1 3803/4885FABP5 4319/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | KMT2A 2798/4885PARP1 3782/4885FABP5 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.